4EVER - Efficacy, Safety, Health Economics, Translational Research of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer (MACS2096)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )
ClinicalTrials.gov Identifier:
NCT01626222
First received: June 20, 2012
Last updated: July 15, 2014
Last verified: July 2014
  Purpose

The present multi-center, open-label, single-arm study aims to evaluate the efficacy and safety, quality of life and health resources utilization in postmenopausal women with hormone receptor positive breast cancer progressing following prior therapy with non-steroidal aromatase inhibitors (NSAI) treated with the combination of Everolimus and Exemestane.


Condition Intervention Phase
Metastatic Breast Cancer
Drug: Exemestane
Drug: Everolimus (RAD001)
Phase 3

Study Type: Interventional
Study Design: Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase IIIB, Multi-Center, Open Label Study For Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Treated With Everolimus (RAD001) in Combination With Exemestane: 4EVER - Efficacy, Safety, Health Economics, Translational Research

Resource links provided by NLM:


Further study details as provided by Novartis:

Primary Outcome Measures:
  • Overall Response Rate (ORR) after 24 weeks of treatment [ Time Frame: 24 weeks ] [ Designated as safety issue: No ]
    The Overall response rate (ORR) is the proportion of patients with a best overall response of confirmed complete (CR) or partial (PR) response by Week 24. The best overall response is determined from the sequence of investigator overall lesion responses according to RECIST 1.1. To be assigned a best overall response of CR at least two determinations of CR at least 4 weeks apart before progression are required. To be assigned a best overall response of PR at least two determinations of PR or better at least 4 weeks apart before progression (and not qualifying for a CR) are required.


Secondary Outcome Measures:
  • Progression free survival (PFS) after 48 weeks of treatment [ Time Frame: 48 weeks ] [ Designated as safety issue: No ]
    Progression-free survival (PFS) is the time from date of start of treatment to the date of event defined as the first documented progression or death due to any cause. If a patient has not had an event, progression-free survival is censored at the date of last adequate tumor assessment.

  • Overall Response Rate (ORR) after 48 weeks of treatment [ Time Frame: 48 weeks ] [ Designated as safety issue: No ]
    The ORR by Week 48 will be derived from the sequence of overall lesion responses as described for the primary efficacy variable. The ORR by Week 48 will be summarized using frequency tables presenting absolute and relative frequencies together with appropriate confidence intervals

  • Overall survival (OS) after 48 weeks of treatment [ Time Frame: 48 weeks ] [ Designated as safety issue: No ]
    Overall survival (OS) is defined as the time from date of start of treatment to date of death due to any cause. If a patient is not known to have died, survival will be censored at the date of last contact. OS will be summarized using the Kaplan-Meier method.

  • Safety within 48 weeks of treatment [ Time Frame: 48 weeks ] [ Designated as safety issue: Yes ]
    The assessment of safety will be based mainly on the frequency of adverse events and on the number of laboratory values that fall outside of pre-determined ranges. Other safety data (e.g. vital signs, and special tests) will be considered as appropriate. For all safety analyses, the safety set will be used.

  • Resource utilization [ Time Frame: 48 weeks ] [ Designated as safety issue: No ]

    Data relating to Resource Utilization will be used for the purpose of economic evaluation, which will be carried out and reported as a separate activity.

    The study population receiving RAD001 plus Exemestane will be compared to alternative cohorts (e.g., purely endocrine treatment with Fulvestrant monotherapy, Exemestane monotherapy or chemotherapy, e.g. Capecitabine) using a Markov model. For each alternative therapy option, median PFS, OS and health-related quality of life will be determined by a systematic review of literature or databases.


  • Health-related quality of life [ Time Frame: 48 weeks ] [ Designated as safety issue: No ]
    Health-related quality of life (HRQoL) will be assessed using the EORTC QLQ-C30 and BR23 questionnaires and the EuroQoL EQ-5D questionnaire. The HADS D questionnaire will be used to assess anxiety and depression. Scoring will follow the instructions of the respective manuals.


Enrollment: 301
Study Start Date: June 2012
Study Completion Date: December 2013
Primary Completion Date: December 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Everolimus & Exemestane
This study will be performed in 300 postmenopausal women with hormone receptor positive locally advanced or metastatic breast cancer progressing following prior therapy with non-steroidal aromatase inhibitors (NSAI) as defined by: 1. Recurrence while on or after completion of an adjuvant treatment including Letrozole or Anastrozole, or 2. Progression while on or following the completion of Letrozole or Anastrozole treatment for locally advanced or metastatic breast cancer. Except for prior use of mTOR inhibitors, there are no restrictions as to the last anticancer treatment prior to enrollment. Patients must have documented evidence of recurrence or progression on last therapy prior to enrollment. Written informed consent must be obtained prior to any screening procedures. The investigator or designee must ensure that only patients who meet all the following inclusion and none of the exclusion criteria are offered enrollment in the study.
Drug: Exemestane
Exemestane is supplied by Novartis until Everolimus is commercially available for the study setting. Afterwards the investigator will prescribe Exemestane according to the individual label. Commercially available Exemestane will be supplied as tablets of 25 mg strength for oral administration. Complete guidelines for management and administration of Exemestane can be found in the package insert. Exemestane will be dosed starting on treatment Day 1. Patients will be instructed to take 1 tablet of 25 mg Exemestane orally. Package insert instructions should be followed. On the first day of each cycle, patients will receive an adequate drug supply (before commercial availability) or a prescription (after commercial availability) for self-administration at home. The investigator must emphasize compliance and will instruct the patient to take Exemestane exactly as prescribed.
Drug: Everolimus (RAD001)
Everolimus (RAD001) is supplied by Novartis until Everolimus is commercially available for the study setting. Afterwards the investigator will prescribe Everolimus according to the individual label. Everolimus is formulated as tablets of 10 and 5 mg strength for oral administration. All study medication will be packaged into blister packs. The blisters should be opened only at the time of administration, as the drugs are both hygroscopic and light sensitive. Everolimus will be dosed starting on treatment Day 1. Patients will be instructed to take 1 tablet × 10 mg Everolimus orally with a large glass of water once daily at the same time each day with or without food. On the first day of each cycle, patients will receive an adequate drug supply (before commercial availability) or a prescription (after commercial availability) for self-administration at home. The investigator must emphasize compliance and will instruct the patient to take Everolimus exactly as prescribed.

Detailed Description:

In light of the need for new treatment options for postmenopausal, hormone receptor positive, HER2 negative women after failure of prior non-steroidal aromatase inhibitor (NSAI) therapy, the BOLERO-2 trial was performed and demonstrated significant efficacy of the combinatorial treatment of Everolimus and Exemestane compared to an Exemestane monotherapy in this setting.

In this randomized, double blind, placebo-controlled trial a statistically significant improvement in progression-free survival (PFS) by adding Everolimus to exemestane versus Exemestane alone was reported. Adding Everolimus determined a 2.4-fold prolongation in PFS from 3.2 up to 7.4 months and so lowered the risk of cancer progression by 56% for these women. These findings were confirmed by an independent assessment (4.1 vs. 11.0 months, risk reduction: 64%). The quality of life data shows positive trend in the Everolimus plus Exemestane treatment arm. (Baselga 2011, Hortobagyi 2011). Thus, the benefit of the combinatorial treatment versus Exemestane monotherapy was shown in a defined patient population under controlled conditions.

The primary objective of this trial to assess the Overall Response Rate (ORR) in postmenopausal women with hormone receptor positive breast cancer progressing following prior therapy with NSAIs treated with the combination of Everolimus and Exemestane. The secondary objectives include, Progression free survival (PFS), Overall survival (OS), Safety, Change in Quality of life scores over time, Health resource utilization. The exploratory objectives reflect scientific interest within the treatment of metastatic breast cancer and are to be modified, if applicable, according to the current scientific state of the art at the time of actual analysis. These include: the influence of age, performance status, cancer activity and inflammation on anxiety and depression; changes in serum bone-turnover biomarkers; Pharmacogenetics of Everolimus in patients with advanced breast cancer; presence and molecular characteristics of Circulating Tumor Cells; correlation of response to Exemestane/Everolimus with Proteomic analysis.

The present national, multi-center, open-label, single-arm study aims to evaluate the efficacy and safety, quality of life and health resources utilization of the combination of Everolimus and Exemestane in a broader patient population compared to BOLERO-2, i.e. without limitations as to the number of previous chemotherapy lines, the time point of progression after NSAI therapy, and the previous endocrine therapy as patients under Exemestane monotherapy may be enrolled. Since the combination was shown to significantly improve PFS in the previous BOLERO-2 trial, for ethical reasons no endocrine comparator drugs will be investigated in the present study, due to the low efficacy of Exemestane monotherapy (PFS 3.2 months).

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Main Inclusion criteria:

Metastatic or locally advanced breast cancer not amenable to curative treatment by surgery or radiotherapy or any other non-systemic treatment.

Histological or cytological confirmation of estrogen receptor positive (ER+) and/or progesterone receptor positive (PgR+), human epidermal growth factor receptor 2 (HER2) negative breast cancer Postmenopausal women. Disease progression following prior therapy with non steroidal aromatase inhibitors (NSAI), defined as: Recurrence while on, or following completion of an adjuvant treatment with Letrozole or Anastrozole, or Progression while on or following completion of Letrozole or Anastrozole treatment for ABC/MBC.

Radiological evidence of recurrence or progression on last systemic therapy prior to enrollment.

Patients must have at least one lesion that can be accurately measured or bone lesions: lytic or mixed (lytic + sclerotic) in the absence of measurable disease.

Written informed consent obtained before any screening procedure and according to local guidelines.

Other protocol defined inclusion criteria apply.

Main Exclusion criteria:

HER2-overexpressing patients by local laboratory testing (IHC 3+ staining or in situ hybridization positive).

Patients with only non-measurable lesions other than bone metastasis (e.g. pleural effusion, ascites etc.).

Previous treatment with mTOR inhibitors or known hypersensitivity to mTOR inhibitors.

Symptomatic brain or other CNS metastases. Previously treated brain metastases are allowed provided the patient is free of symptoms, prior radiotherapy for brain metastasis was more than four weeks before enrollment and the dose of corticosteroids is low (i.e. ≤ 10 mg/d Prednisolone equivalent) and stable for at least two weeks prior to enrollment.

Patients with Hepatitis B or C or with a history of Hepatitis B or C. Patients unwilling to or unable to comply with the protocol. Other protocol defined exclusion criteria apply.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01626222

  Hide Study Locations
Locations
Germany
Novartis Investigative Site
Aachen, Germany, 52074
Novartis Investigative Site
Amberg, Germany, 92224
Novartis Investigative Site
Augsburg, Germany, 86156
Novartis Investigative Site
Augsburg, Germany, 86150
Novartis Investigative Site
Bergisch Gladbach, Germany, 51465
Novartis Investigative Site
Berlin, Germany, 12552
Novartis Investigative Site
Berlin, Germany, 14169
Novartis Investigative Site
Berlin, Germany, 12683
Novartis Investigative Site
Berlin, Germany, 14195
Novartis Investigative Site
Berlin, Germany, 12200
Novartis Investigative Site
Berlin, Germany, 10707
Novartis Investigative Site
Berlin, Germany, 10367
Novartis Investigative Site
Bochum, Germany, 44787
Novartis Investigative Site
Bonn, Germany, 53105
Novartis Investigative Site
Bonn, Germany, 53111
Novartis Investigative Site
Bottrop, Germany, 46236
Novartis Investigative Site
Braunschweig, Germany, 38100
Novartis Investigative Site
Bremen, Germany, 28209
Novartis Investigative Site
Böblingen, Germany, 71032
Novartis Investigative Site
Chemnitz, Germany, 09116
Novartis Investigative Site
Donauwoerth, Germany, 86609
Novartis Investigative Site
Dresden, Germany, 01127
Novartis Investigative Site
Duesseldorf, Germany, 40225
Novartis Investigative Site
Erlangen, Germany, 91054
Novartis Investigative Site
Essen, Germany, 45147
Novartis Investigative Site
Essen, Germany, 45136
Novartis Investigative Site
Esslingen, Germany, 73730
Novartis Investigative Site
Eutin, Germany, 23701
Novartis Investigative Site
Frankfurt, Germany, 60590
Novartis Investigative Site
Frankfurt, Germany, 60389
Novartis Investigative Site
Freiburg, Germany, 79106
Novartis Investigative Site
Fuerstenwalde, Germany, 15517
Novartis Investigative Site
Fuerth, Germany, 90766
Novartis Investigative Site
Fulda, Germany, 36043
Novartis Investigative Site
Gera, Germany, 07548
Novartis Investigative Site
Gerlingen, Germany, 70839
Novartis Investigative Site
Goslar, Germany, 38642
Novartis Investigative Site
Gütersloh, Germany, 33332
Novartis Investigative Site
Halle, Germany, 06110
Novartis Investigative Site
Halle/'Saale, Germany, 06120
Novartis Investigative Site
Hamburg, Germany, 20249
Novartis Investigative Site
Hannover, Germany, 30177
Novartis Investigative Site
Heidelberg, Germany, 69120
Novartis Investigative Site
Jena, Germany, 07740
Novartis Investigative Site
Kassel, Germany, 34125
Novartis Investigative Site
Kiel, Germany, 24105
Novartis Investigative Site
Kiel, Germany, 24103
Novartis Investigative Site
Koeln, Germany, 50935
Novartis Investigative Site
Köln, Germany, 50924
Novartis Investigative Site
Langen, Germany, 63225
Novartis Investigative Site
Lemgo, Germany, 32657
Novartis Investigative Site
Lüneburg, Germany, 21339
Novartis Investigative Site
Magdeburg, Germany, 39120
Novartis Investigative Site
Mainz, Germany, 55131
Novartis Investigative Site
Mannheim, Germany, 68165
Novartis Investigative Site
Marburg, Germany, 35039
Novartis Investigative Site
Memmingen, Germany, 87700
Novartis Investigative Site
Muelheim, Germany, 45468
Novartis Investigative Site
Muenchen, Germany, 81241
Novartis Investigative Site
Muenchen, Germany, 81377
Novartis Investigative Site
Muenchen, Germany, 80637
Novartis Investigative Site
Muenster, Germany, 48149
Novartis Investigative Site
Mönchengladbach, Germany, 41061
Novartis Investigative Site
Mühlhausen, Germany, 99974
Novartis Investigative Site
München, Germany, 80638
Novartis Investigative Site
Nuernberg, Germany, 90403
Novartis Investigative Site
Oldenburg, Germany, 26121
Novartis Investigative Site
Plauen-Kauschwitz, Germany, 08525
Novartis Investigative Site
Ravensburg, Germany, 88214
Novartis Investigative Site
Recklinghausen, Germany, 45657
Novartis Investigative Site
Rosenheim, Germany, 83022
Novartis Investigative Site
Rostock, Germany, 18057
Novartis Investigative Site
Singen, Germany, 78224
Novartis Investigative Site
Soest, Germany, 59494
Novartis Investigative Site
Speyer, Germany, 67346
Novartis Investigative Site
Stralsund, Germany, 18435
Novartis Investigative Site
Stuttgart, Germany, 70190
Novartis Investigative Site
Trier, Germany, 54290
Novartis Investigative Site
Troisdorf, Germany, 53840
Novartis Investigative Site
Tuebingen, Germany, 72076
Novartis Investigative Site
Velbert, Germany, 42551
Novartis Investigative Site
Villingen-Schwenningen, Germany, 78052
Novartis Investigative Site
Weißenfels, Germany, 06667
Novartis Investigative Site
Wuppertal, Germany, 42105
Sponsors and Collaborators
Novartis Pharmaceuticals
Investigators
Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals
  More Information

No publications provided

Responsible Party: Novartis ( Novartis Pharmaceuticals )
ClinicalTrials.gov Identifier: NCT01626222     History of Changes
Other Study ID Numbers: CRAD001JDE49
Study First Received: June 20, 2012
Last Updated: July 15, 2014
Health Authority: Germany: Federal Institute for Drugs and Medical Devices

Keywords provided by Novartis:
Postmenopausal
Estrogen Receptor Positive
HER2 negative
Locally Advanced
Metastatic Breast Cancer
Everolimus (RAD001)
Exemestane

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases
Estrogens
Exemestane
Sirolimus
Everolimus
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Pharmacologic Actions
Antineoplastic Agents
Therapeutic Uses
Aromatase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Immunosuppressive Agents
Immunologic Factors
Anti-Bacterial Agents
Anti-Infective Agents
Antibiotics, Antineoplastic
Antifungal Agents

ClinicalTrials.gov processed this record on August 20, 2014